We all heard about the DePuy + S&N merger talks fell through last week. The media framed the late collapse of the DePuy Synthes–Smith+Nephew talks as a pure corner-office fight: J&J wanted Namal Nawana to run the combined ~$34 billion company; S&N chair Rupert Soames said Deepak Nath was non-negotiable. Financial terms were supposedly locked. Then nothing. That framing is convenient. It lets everyone look sophisticated while ignoring the more basic reasons this combination was always a non-starter. Below is my analysis on the real WHY. Overlap, not “synergies” Both companies are heavy in the same places—hips, knees, trauma, and related instrumentation. A deal this size does not produce elegant portfolio rationalization; it produces overlapping manufacturing plants, overlapping sales forces, overlapping R&D, and overlapping admin. In practice that means large-scale reductions. Industry veterans who have lived through these combinations put the number of people who lose jobs on the smaller side at roughly half. The public dispute was never really about who was the better CEO. It was about who got to decide which half got fired and which facilities closed. S&N’s ...
Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !

